Abstract:178 Background: Anti-EGFR therapy has the potential to increase a localized anti-tumor immune response. We recently published the results of a phase Ib/II trial of the anti-EGFR antibody cetuximab in combination with the anti-PD1 antibody pembrolizumab in pts with advanced, RASwt CRC (PMID: 34645646). Despite its partial local immunologic efficacy, this combination of cetuximab and pembrolizumab was inactive. Here we present the results of comprehensive molecular characterization of pts with tumors amenable to DNA and RNA sequencing. Methods: Forty-two pts with RASwt mCRC were treated with cetuximab plus pembrolizumab. Archival or fresh tumor samples were obtained at baseline and, in select patients, on-treatment. Tumor samples underwent targeted DNA sequencing and whole transcriptome sequencing. Gene set enrichment analysis (GSEA), metabolic dysregulation assessment, and immune deconvolution were performed. Genomic data were linked to clinical outcomes. Results: Eighteen pts had tissue available for dual DNA/RNA extraction and sequencing. Of these, 10 had available matched on-treatment tumor samples. The most common mutations detected in protein coding regions were TP53 (14 pts), ERBB4 (5 pts), CDKN2A and APC (6 pts each). There were no statistically significant differences in progression-free survival (PFS) in pts with and without resistance-associated mutations (i.e., RAS, MET, ERBB4). Further, there was no significant difference associated with the consensus molecular subtype (CMS). However, when we compared patients with stable/increased tumor change percentage to those with decreased tumor change percentage, we found downstream transcriptional differences associated with altered metabolism, and in particular lipid and amino acid metabolism. Conclusions: We identified a significant number of patients with mutations predicting resistance to either or both cetuximab and pembrolizumab; however, none were associated with survival. However, we did identify metabolic pathways of interest, which may be associated with response to therapy. It is important to note, our analysis is limited by the small number of specimens (Trial registration NCT02713373). Clinical trial information: NCT02713373 .

Molecular mechanisms of cetuximab resistance in metastatic colorectal cancer

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

CCR7 High Expression Leads to Cetuximab Resistance by Cross-Talking with EGFR Pathway in PI3K/AKT Signals in Colorectal Cancer

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Identification and Prognostic Analysis of the Cetuximab Resistance-Related Gene REV1 in RAS Wild-Type Metastatic Colorectal Cancer.

Efficacy and Immune Mechanisms of Cetuximab for the Treatment of Metastatic Colorectal Cancer

Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer

Mechanisms of Resistance to Anti-Egfr Therapy in Colorectal Cancer

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.

Cetuximab-Induced Met Activation Acts As A Novel Resistance Mechanism In Colon Cancer Cells

Lncrna MIR100HG-derived Mir-100 and Mir-125B Mediate Cetuximab Resistance Via Wnt/β-catenin Signaling.

Transcriptome Alterations In Liver Metastases Of Colorectal Cancer After Acquired Resistance To Cetuximab

Dynamic Alterations of Genome and Transcriptome in KRAS G13D Mutant CRC PDX Model Treated with Cetuximab.

LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways

Exprimental research on K-ras mutation and the resistance to cetuximab

Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression

Research advances in mechanism of noncoding RNAs in the resistance to anti-epidermal growth factor receptor therapy in colorectal cancer

Mtor Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations.

Research progress of resistance mechanisms and restoring sensitivity to anti-EGFR mon-oclonal antibodies in metastatic colorectal cancer

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer